John A Greiner

US Patent:

20040091995, May 13, 2004

Filed:

Jul 16, 2003

Appl. No.:

10/297168

Inventors:

Jeffrey Schlom - Potomac MD, US
John Greiner - Ijamsville MD, US
Erik Kass - Chevy Chase MD, US
Dennis Panicali - Acton MA, US

International Classification:

A61K039/275
A61K039/285
C12N007/00
A61K048/00

US Classification:

435/235100, 424/232100, 424/093200

Abstract:

Replication-defective recombinant poxvirus encoding granulocyte-macrophage colony-stimulating factor (GM-CSF) are disclosed for use in enriching an immunization site with antigen-presenting cells (APC), for enhancing an immunological response to antigen or immunological epitopes by functioning as a biological adjuvant, for prevention or treatment of neutropenia, and for the treatment of myeloidysplastic syndromes. Compositions comprising a replication-defective recombinant virus encoding GM-CSF alone or in combination with a recombinant virus encoding an antigen and optionally encoding an immunostimulatory molecule are disclosed for enhancing antigen-specific immunological responses, in particular enhancing tumor antigen responses for anti-tumor therapy. Methods for enriching an immunization site with APC and for enhancing immunological responses to an antigen or immunological epitope using replication-defective recombinant poxvirus encoding GM-CSF are disclosed. The superiority of the use of a replication-defective recombinant avian poxvirus encoding GM-CSF over the use of recombinant GM-CSF is described.

US Patent:

20100150960, Jun 17, 2010

Filed:

Sep 21, 2007

Appl. No.:

12/442483

Inventors:

Jeffrey Schlom - Potomac MD, US
David A. Zaharoff - Fayetteville AR, US
John W. Greiner - Ijamsville MD, US

Assignee:

The United States of America, as represented by the Secretary,Department of Health and Human Servi - BETHESDA MD

International Classification:

A61K 39/21
A61K 39/00
A61P 31/12
A61K 39/145
A61K 39/29
A61K 39/015
A61K 38/19
A61P 37/04
A61P 31/16
A61P 31/18
A61P 35/00

US Classification:

4242081, 4241841, 4242091, 4242251, 4242721, 514 12, 977773

Abstract:

The present invention features methods and compositions related to chitosan antigen depots, and chitosan cytokine depots, and the use of depot compositions in treating and preventing diseases.